BP Boardroom Turmoil Deepens as Chairman Manifold Departs SP 500 Edges Higher as Healthcare and Tech Lead Communication Services Weighs Kevin Hassett Praises Record Credit Card Spending Amid Rising Delinquencies and 46 Surge in Farm Bankruptcies Reddit Shares Decline Nearly 6 Following Metas Launch of Forum App Kazatomprom Reports 17 Production Increase in Q3 Bolstering Uranium Supply Outlook Micron Stock Faces Valuation Scrutiny Amid Memory Cycle Concerns VTRS Q1 2026 Earnings Strong EPS Beat of 1517 Surprise Amid Stable Execution Youdao Inc Q1 2026 Earnings EPS Misses Estimates but Stock Surges on Broader Sentiment Mannatech MTEX Q3 2023 Earnings Slim Profit Amid Quiet Market Reaction SANUWAVE Health Q1 2026 Earnings EPS Misses Estimates by 2838 Revenue Not Disclosed ASST Q1 2026 Earnings EPS Misses Estimates by Wide Margin Amid PreRevenue Phase BYND Q1 2026 Earnings EPS Surprises to the Upside Amid Continuing Operational Restructuring Energy Focus EFOI Inches Higher Testing Key Resistance Near 409 New Found Gold Corp NFGC Surges 556 Testing Key Resistance at 21 Rogers Communications RCI Gains 148 as Shares Approach Resistance at 3905 Viavi Solutions VIAV Slips Over 3 as Shares Test Key Support Levels Cathay General Bancorp CATY Holds Steady Near Support Eyes Resistance Ahead Geopolitical Tensions Escalate as Iran Refuses to Bow Trump Rejects Peace Offer Potentially Impacting Global Energy Markets APG Q1 2026 Earnings EPS Exceeds Expectations Amid Steady Operational Performance MARA Holdings Experiences Modest Decline Amidst Crypto Market Uncertainty AVTX Q1 2026 Earnings Narrowed Loss Beats Street Estimates as Pipeline Advances Hilltop Holdings Inc Q1 2026 Earnings EPS Beat Surprises Analysts by 30 Roper Technologies Q1 2026 Earnings EPS Beats Estimates as Margins Drive Performance Nicolet Bankshares Inc Q1 2026 Earnings Significant EPS Miss Amid Challenging Banking Environment OLN Q1 2026 Earnings Surprising EPS Beat Amid Challenging Market CTO Q1 2026 Earnings Massive EPS Beat as Earnings Surge Past Estimates Kalaris Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid PreRevenue Biotech